A citation-based method for searching scientific literature

Sherene Loi, Damien Drubay, Sylvia Adams, Giancarlo Pruneri, Prudence A Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria, Robert Gray, Elisabetta Munzone, Jerome Lemonnier, Christos Sotiriou, Martine J Piccart, Pirkko-Liisa Kellokumpu-Lehtinen, Andrea Vingiani, Kathryn Gray, Fabrice Andre, Carsten Denkert, Roberto Salgado, Stefan Michiels. J Clin Oncol 2019
Times Cited: 277







List of co-cited articles
730 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, S Wienert, G Van den Eynden, F L Baehner, F Penault-Llorca,[...]. Ann Oncol 2015
49

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
708
44

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
37

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
551
35

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, Françoise Van Eenoo, Ghizlane Rouas, Prudence Francis, John P A Crown, Erika Hitre,[...]. J Clin Oncol 2013
978
27

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Sylvia Adams, Robert J Gray, Sandra Demaria, Lori Goldstein, Edith A Perez, Lawrence N Shulman, Silvana Martino, Molin Wang, Vicky E Jones, Thomas J Saphner,[...]. J Clin Oncol 2014
739
25

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
24

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
23

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
J H Park, S F Jonas, G Bataillon, C Criscitiello, R Salgado, S Loi, G Viale, H J Lee, M V Dieci, S-B Kim,[...]. Ann Oncol 2019
77
27


Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Carsten Denkert, Gunter von Minckwitz, Jan C Brase, Bruno V Sinn, Stephan Gade, Ralf Kronenwett, Berit M Pfitzner, Christoph Salat, Sherene Loi, Wolfgang D Schmitt,[...]. J Clin Oncol 2015
615
20

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L Telli,[...]. Lancet 2020
212
20

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Carsten Denkert, Sibylle Loibl, Aurelia Noske, Marc Roller, Berit Maria Müller, Martina Komor, Jan Budczies, Silvia Darb-Esfahani, Ralf Kronenwett, Claus Hanusch,[...]. J Clin Oncol 2010
19

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Peter Schmid, Hope S Rugo, Sylvia Adams, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Volkmar Henschel, Luciana Molinero, Stephen Y Chui,[...]. Lancet Oncol 2020
395
19

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, P-L Kellokumpu-Lehtinen, P Bono, V Kataja, C Desmedt,[...]. Ann Oncol 2014
768
18

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Javier Cortes, David W Cescon, Hope S Rugo, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H Barrios, Esther Holgado,[...]. Lancet 2020
307
18

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Peter Savas, Roberto Salgado, Carsten Denkert, Christos Sotiriou, Phillip K Darcy, Mark J Smyth, Sherene Loi. Nat Rev Clin Oncol 2016
416
16

PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M Gonzalez-Angulo, Argun Akcakanat,[...]. Cancer Immunol Res 2014
667
16

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
S Adams, P Schmid, H S Rugo, E P Winer, D Loirat, A Awada, D W Cescon, H Iwata, M Campone, R Nanda,[...]. Ann Oncol 2019
305
16

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Rita Nanda, Minetta C Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne Wallace, A Jo Chien, Andres Forero-Torres, Erin Ellis, Heather Han,[...]. JAMA Oncol 2020
185
15

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A Emens, Cristina Cruz, Joseph Paul Eder, Fadi Braiteh, Cathie Chung, Sara M Tolaney, Irene Kuter, Rita Nanda, Philippe A Cassier, Jean-Pierre Delord,[...]. JAMA Oncol 2019
323
15

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Leonie Voorwerk, Maarten Slagter, Hugo M Horlings, Karolina Sikorska, Koen K van de Vijver, Michiel de Maaker, Iris Nederlof, Roelof J C Kluin, Sarah Warren, SuFey Ong,[...]. Nat Med 2019
284
15

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
619
14

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim,[...]. N Engl J Med 2017
619
14

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Maria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, Gert van den Eynden, Nils Ternes, Frederique Penault-Llorca, Giancarlo Pruneri, Timothy M D'Alfonso, Sandra Demaria, Carlos Castaneda,[...]. Semin Cancer Biol 2018
174
14


Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
13

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng,[...]. J Clin Oncol 2016
843
13

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
Zuzana Kos, Elvire Roblin, Rim S Kim, Stefan Michiels, Brandon D Gallas, Weijie Chen, Koen K van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria,[...]. NPJ Breast Cancer 2020
44
29


Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
12

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, Petros Nikolinakos, Hendrik-Tobias Arkenau, Andres Forero-Torres, Ralph Boccia, Marc E Lippman, Robert Somer, Martin Smakal,[...]. Breast Cancer Res Treat 2018
337
11

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
H R Ali, E Provenzano, S-J Dawson, F M Blows, B Liu, M Shah, H M Earl, C J Poole, L Hiller, J A Dunn,[...]. Ann Oncol 2014
411
11

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
M V Dieci, M C Mathieu, V Guarneri, P Conte, S Delaloge, F Andre, A Goubar. Ann Oncol 2015
180
11

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Paula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, Emily Reisenbichler, Zuzana Kos, Jodi M Carter, Stefan Michiels, John Le Quesne, Torsten O Nielsen, Anne-Vibeke Laenkholm,[...]. J Pathol 2020
77
12

Immunological differences between primary and metastatic breast cancer.
B Szekely, V Bossuyt, X Li, V B Wali, G A Patwardhan, C Frederick, A Silber, T Park, M Harigopal, V Pelekanou,[...]. Ann Oncol 2018
130
10

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
Katherine E Hutchinson, Susan E Yost, Ching-Wei Chang, Radia Marie Johnson, Adrian R Carr, Paul R McAdam, Daniel L Halligan, Chun-Chieh Chang, Daniel Schmolze, Jackson Liang,[...]. Clin Cancer Res 2020
37
27

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
10

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, Xi Chen, Monica V Estrada, Kimberly N Johnson, Yu Shyr, Harold L Moses, Melinda E Sanders, Jennifer A Pietenpol. PLoS One 2016
543
10

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.
Sahar M A Mahmoud, Emma Claire Paish, Desmond G Powe, R Douglas Macmillan, Matthew J Grainge, Andrew H S Lee, Ian O Ellis, Andrew R Green. J Clin Oncol 2011
905
10

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
305
9

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
H J Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, M Colleoni, C Denkert, M Piccart-Gebhart, M Regan,[...]. Ann Oncol 2019
265
9

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
P Schmid, R Salgado, Y H Park, E Muñoz-Couselo, S B Kim, J Sohn, S-A Im, T Foukakis, S Kuemmel, R Dent,[...]. Ann Oncol 2020
112
9

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
Thomas Karn, Tingting Jiang, Christos Hatzis, Nicole Sänger, Ahmed El-Balat, Achim Rody, Uwe Holtrich, Sven Becker, Giampaolo Bianchini, Lajos Pusztai. JAMA Oncol 2017
81
11

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
F Poggio, M Bruzzone, M Ceppi, N F Pondé, G La Valle, L Del Mastro, E de Azambuja, M Lambertini. Ann Oncol 2018
154
9

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.
Peter Savas, Balaji Virassamy, Chengzhong Ye, Agus Salim, Christopher P Mintoff, Franco Caramia, Roberto Salgado, David J Byrne, Zhi L Teo, Sathana Dushyanthen,[...]. Nat Med 2018
395
9

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.
Carsten Denkert, Stephan Wienert, Audrey Poterie, Sibylle Loibl, Jan Budczies, Sunil Badve, Zsuzsanna Bago-Horvath, Anita Bane, Shahinaz Bedri, Jane Brock,[...]. Mod Pathol 2016
149
9

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
9

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
F Cardoso, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, I T Rubio, S Zackrisson, E Senkus. Ann Oncol 2019
488
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.